Peer-reviewed research, conference presentations, and patent filings underpinning SBC003's scientific foundation.
SunRegen's science is publicly documented. SBC003's mechanism of action, preclinical efficacy, and safety profile have been presented at international ophthalmology conferences and published in peer-reviewed journals. The foundational Aging Cell publication (2022) is open-access and freely available.
Oamen HP, Amos A, Obaniyi J, Obi I, Dong Y, et al.
Aging Cell
SBC003, a rare natural glycerolipid, was found to induce neuroglobin expression via p-body modulation, protecting neurons against multiple toxic protein aggregates including amyloid-β, α-synuclein, prion protein, tau, and amylin oligomers. In vivo studies in rhesus monkeys with naturally occurring optic atrophy demonstrated significant RNFL recovery following oral administration.
Dong Y, et al.
Investigative Ophthalmology & Visual Science (IOVS) — ARVO 2020
Dose-dependent neuroprotection of SBC003 was demonstrated in NMU-induced retinal degeneration (C57BL/6J mice). Outer nuclear layer preservation significantly increased at 50 mg/kg (83.08 ± 19.05 vs. vehicle 43.46 ± 29.86, p<0.001). OCT confirmed significantly increased neuroretinal thickness across peripheral, mid-peripheral, and central retina.
Dong Y (inventor); SunRegen Healthcare AG (applicant)
PCT/CN2017/101545 — WO2017211274A1
Patent covering use of SBC003 and related odd-chain lipids for neurodegenerative diseases, degenerative optic and retinal diseases, demyelinating diseases, and neuromuscular disorders. Granted in 8 countries including US, Canada, Japan, and China.
Summary of statistically significant findings from peer-reviewed SBC003 research.
Neuroglobin induction
5.91×
Fold-increase in neuroglobin expression in mouse primary cortex neurons at 1 μM SBC003 at 3 hours.
Aging Cell, 2022
Photoreceptor preservation (ONL)
p<0.001
Outer Nuclear Layer preservation: 83.08 ± 19.05 (50 mg/kg SBC003) vs. 43.46 ± 29.86 (vehicle) in NMU-induced retinal degeneration.
IOVS / ARVO, 2020
RNFL recovery in primates
p<0.005
Significant RNFL thickness increase in diseased eyes of rhesus monkeys with naturally occurring optic atrophy after oral SBC003. No change in healthy contralateral eyes.
Aging Cell, 2022
Human iPSC neuron efficacy
Higher efficiency
SBC003 protected human iPSC-derived neurons from amyloid-β oligomers with higher efficiency than mouse primary neurons, supporting translational relevance.
Aging Cell, 2022
Scientific Disclosure Notice
SBC003 is investigational and has not been approved by the FDA, EMA, or any other regulatory authority for any indication. Preclinical data presented here are from animal models and in vitro studies; they may not predict human outcomes.
All data are sourced from peer-reviewed publications and publicly presented conference abstracts. SunRegen makes no claims regarding safety or efficacy in humans at this stage of development.
Pioneering first-in-class orally bioavailable lipid therapeutics to halt neurodegeneration and restore vision. Clinical-stage. Basel, Switzerland.
© 2026 SunRegen Healthcare AG. All rights reserved.
Business Parc Reinach, Christoph Merian-Ring 11, 4153 Reinach, Switzerland
UID: CHE-295.245.274
This website contains forward-looking statements regarding future products, development plans, and business strategies. Actual results may differ materially. Nothing on this site constitutes medical or investment advice.